Skip to main content
SpringerLink
Log in

Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen

  • Chapter
Molekularmedizinische Grundlagen von hämatologischen Neoplasien

Part of the book series: Molekulare Medizin ((MOLMED))

  • 145 Accesses

Zusammenfassung

Unter dem Oberbegriff der chronischen myeloproliferativen Erkrankungen (CMPE) fassen wir

  • die chronische myeloische Leukämie (CML),

  • die Polycythaemia vera (PV),

  • die idiopathische Osteomyelofibrose (OMS) und

  • die essenzielle Thrombozythämie (ET)

zusammen. Die CMPE treten sporadisch auf, gehen somit auf erworbene und nicht auf angeborene klonale genetische Veränderungen zurück. In allen Fällen sind als Ausgangszellen pluripotente hämatopoetische Stammzellen anzunehmen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954–2970

    PubMed  CAS  Google Scholar 

  • Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloprolifearative disorders. Baillieres Clin Haematol 11:819–848

    Article  PubMed  CAS  Google Scholar 

  • Ben Neriah Y, Daley GQ, Mes Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212–214

    Article  Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT et al. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposal by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87:746–754

    Article  PubMed  CAS  Google Scholar 

  • Berk D, Goldberg JD, Donovan PB, Fruchtman SM, Berlin MI, Wasserman LR (1986) Therapeutic recommendations in polycythemia vera based on polycythemia study group protocols. Semin Hematol 23:132–143

    PubMed  CAS  Google Scholar 

  • Blanchard KL, Gilliland DG, Bunn HF (1992) Clonality in myeloproliferative disorders. Am J Med Sci 304:125–130

    Article  PubMed  CAS  Google Scholar 

  • Chissoe SL, Bodenteich A, Wang YF et al. (1995) Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27:67–82

    Article  PubMed  CAS  Google Scholar 

  • Chronic Myeloid Leukemia Trialist’s Collaborative Group (1997) Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616–1620

    Article  Google Scholar 

  • Clift RA, Appelbaum FR, Thomas ED (1993) Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954–1956

    PubMed  CAS  Google Scholar 

  • Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830

    Article  PubMed  CAS  Google Scholar 

  • Davis RL, Konopka JB, Witte ON (1985) Activation of the c-abl oncogene by viral transduction generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 5:204–213

    PubMed  CAS  Google Scholar 

  • Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356

    PubMed  CAS  Google Scholar 

  • Demory JL, Dupriez B, Fenaux P et al. (1988) Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855

    PubMed  CAS  Google Scholar 

  • Derderian PM, Kantarjian HM, Talpaz M (1993) Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94:69–74

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Sawyers CL, Kantarjian H et al. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 344:1038–1042

    Article  PubMed  CAS  Google Scholar 

  • Druker BJ, Talpaz M, Resta DJ et al. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    Article  PubMed  CAS  Google Scholar 

  • Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC (1990) Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 75:188–194

    Article  PubMed  CAS  Google Scholar 

  • Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172

    Article  PubMed  CAS  Google Scholar 

  • Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase avctivity and induction of proteasome-mediated degradation. Mol Cel Biol 15:3547–3557

    Article  Google Scholar 

  • Gale RE, Hehlmann R, Zhang M-J et al. (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810–1819

    PubMed  CAS  Google Scholar 

  • Ganesan TS, Rassool R, Guo A-P et al. (1986) Rearrangement of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood 68:957–960

    PubMed  CAS  Google Scholar 

  • Gewirtz AM (1992) Therapeutic applications of antisense DNA in the treatment of human leukemia. Ann N Y Acad Sci 660:178–187

    Article  PubMed  CAS  Google Scholar 

  • Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092

    Article  PubMed  CAS  Google Scholar 

  • Groffen J, Stephenson JR, Heisterkamp N, Klein A de, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93–99

    Article  PubMed  CAS  Google Scholar 

  • Guardiolo P, Anderson JE, Bandini G et al. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and bone marrow transplantation. Blood 93:2831–2838

    Google Scholar 

  • Guilhot F, Chastang C, Michallet M et al. (1997) Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223–229

    Article  PubMed  CAS  Google Scholar 

  • Haferlach T, Winkemann M, Nickenig C et al. (1997) Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 97:99–106

    Article  PubMed  CAS  Google Scholar 

  • Hansen JA, Gooley TA, Martin PJ et al. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968

    Article  PubMed  CAS  Google Scholar 

  • Harrison CN, Gale RE, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia does not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417–422

    PubMed  CAS  Google Scholar 

  • Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 90:850–858

    Article  PubMed  CAS  Google Scholar 

  • Hehlmann R (1998) A chance of cure for every patient with CML? N Engl J Med 338:980–982

    Article  PubMed  CAS  Google Scholar 

  • Hehlmann R, Heimpel H, Hasford J et al. (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 398:398–407

    Google Scholar 

  • Heim S, Mitelman F (1995) Cancer cytogenetics. Wiley-Liss, New York

    Google Scholar 

  • Heisterkamp N, Stephenson JR, Groffen J et al. (1983) Localization of the c-abl oncogene adjactent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239–242

    Article  PubMed  CAS  Google Scholar 

  • Heisterkamp N, Jenster G, Hoeve J ten, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253

    Article  PubMed  CAS  Google Scholar 

  • Hochhaus A, Reiter A, Skladny H et al. (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88:2236–2240

    PubMed  CAS  Google Scholar 

  • Hochhaus A, Reiter A, Saussele S et al. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95:62–66

    PubMed  CAS  Google Scholar 

  • Johansson B, Fioretos T, Billström R, Mitelman F (1996) Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia 10: 1134–1138

    PubMed  CAS  Google Scholar 

  • Kantarjian HM, Keating MJ, Talpaz M (1987) Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 83:445–454

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122:254–261

    PubMed  CAS  Google Scholar 

  • Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050

    PubMed  CAS  Google Scholar 

  • Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035–1042

    Article  PubMed  CAS  Google Scholar 

  • Kramer A, Horner S, Wilier A et al. (1999) Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci USA 96:2087–2092

    Article  PubMed  CAS  Google Scholar 

  • Lange W, Cantin EM, Finke J, Dolken G (1993) In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7:1786–1794

    PubMed  CAS  Google Scholar 

  • Lengfelder E, Berger U, Hehlmann R (2000) Inteferon-α in polycythemia vera. Ann Hematol 79:103–105

    Article  PubMed  CAS  Google Scholar 

  • Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384

    PubMed  CAS  Google Scholar 

  • Melo JV, Myint H, Galton DAG, Goldman JM (1994) P190 BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia 8: 208–211

    PubMed  CAS  Google Scholar 

  • Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma [Suppl 1] 11:11–15

    Article  Google Scholar 

  • Nanjangud G, Kadam PR, Saikia T et al. (1994) Karyotypic findings as an independent prognostic marker in chronic myeloid leukemia blast crisis. Leuk Res 18: 385–392

    Article  PubMed  CAS  Google Scholar 

  • Nowell PC, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497

    Google Scholar 

  • Pane F, Frigeri F, Sindona M et al. (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410–2414 [published erratum appears in Blood 1997 Jun 1;89(11): 4244]

    PubMed  CAS  Google Scholar 

  • Petrides PE, Beykirch MK, Trapp O (1998) Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur J Hematol 61:71–76

    Article  CAS  Google Scholar 

  • Raanani P, Dazzi F, Sohal J et al. (1997) The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99:945–950

    Article  PubMed  CAS  Google Scholar 

  • Radich JP, Gehly G, Gooley T et al. (1995) Polymerase chain-reaction detection for the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implication in 346 patients. Blood 85:2632–2640

    PubMed  CAS  Google Scholar 

  • Rhee F van, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC (1996) pi90 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 87:5213–5217

    PubMed  Google Scholar 

  • Reiter A, Skladny H, Hochhaus A et al. (1997) Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol 97:86–93

    Article  PubMed  CAS  Google Scholar 

  • Reiter A, Sohal J, Kulkarni S et al. (1998) Consistent fusion of ZNF198 to fibroblast growth factos receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92:1735–1742

    PubMed  CAS  Google Scholar 

  • Reiter A, Hehlmann R, Goldman JM, Cross NC (1999) The 8p11 myeloproliferative syndrome. Med Klin 94:207–210

    Article  Google Scholar 

  • Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293

    Article  PubMed  CAS  Google Scholar 

  • Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340

    Article  PubMed  CAS  Google Scholar 

  • Schoch C, Schnittger S, Bursch S et al. (2002) Comparison of chromosome banding analysis, interphase- and hyper-metaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 16:53–59

    Article  PubMed  CAS  Google Scholar 

  • Sill H, Goldman JM, Cross NC (1995) Homozygous deletions of the pl6 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013–2016

    PubMed  CAS  Google Scholar 

  • Sokal JE, Cox EB, Baccarani M et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63:789–799

    PubMed  CAS  Google Scholar 

  • Statistisches Bundesamt (1997) Statistisches Bundesamt: Sterbefälle nach Todesursachen in Deutschland. Einzelnachweis. Statistisches Bundesamt, Wiesbaden

    Google Scholar 

  • Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1263

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Solberg L, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141–149

    Article  PubMed  CAS  Google Scholar 

  • Temerinac S, Klippel S, Strunck E et al. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95:2569–2576

    PubMed  CAS  Google Scholar 

  • Thiele J, Kvasnicka HM (2000) Polyglobulie versus Polycythemia vera. Pathologe 21:24–30

    Article  PubMed  CAS  Google Scholar 

  • Virchow R (1845) Weisses Blut. Frorieps Notizen 36:151–156

    Google Scholar 

Download references

Authors
  1. Torsten Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Schnittger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia Schoch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Str. 10, 13122, Berlin-Buch, Deutschland

    Detlev Ganten  & Klaus Ruckpaul  & 

  2. Intitut für Zell- und Molekularpathologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30623, Hannover, Deutschland

    Brigitte Schlegelberger

  3. Medizinische Fakultät, Institut für Medizinische Biologie, Universität Wien, Währinger Gürtel 10, A-1090, Wien IX, Österreich

    Christa Fonatsch

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Haferlach, T., Schnittger, S., Schoch, C. (2003). Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen. In: Ganten, D., Ruckpaul, K., Schlegelberger, B., Fonatsch, C. (eds) Molekularmedizinische Grundlagen von hämatologischen Neoplasien. Molekulare Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59343-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59343-7_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63941-8

  • Online ISBN: 978-3-642-59343-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation